Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26997338 | 0.85 | LMNA (0.36) | HTR1DTMEM97SIGMAR1PDE2ALMNA | |
| SCHEMBL22357753 | 0.84 | HTR1D (0.43) | HTR1DTMEM97SIGMAR1PDE2ANLRP3 | |
| SCHEMBL20117055 | 0.83 | HTR6 (0.34) | KCNH2OPRD1HTR6HTR4SYK | |
| SCHEMBL26997341 | 0.82 | TMEM97 (0.34) | HTR1DTMEM97SIGMAR1PDE2ANLRP3 | |
| SCHEMBL22357756 | 0.81 | PDE2A (0.40) | TMEM97SIGMAR1PDE2ASYKNLRP3 | |
| SCHEMBL22357755 | 0.80 | MTNR1A (0.37) | KDM4ECNR2LMNANLRP3 | |
| SCHEMBL2758323 | 0.68 | HTR1D (0.55) | HTR1DKCNH2CYP1A2CYP2C19HTR6 | |
| SCHEMBL21025789 | 0.67 | SLC22A12 (0.42) | HTR1DKCNH2KDM4ECYP1A2CYP2C19 | |
| SCHEMBL20116951 | 0.65 | CMKLR1 (0.35) | PDE2ANLRP3 | |
| SCHEMBL21025791 | 0.65 | SLC22A12 (0.41) | HTR1DKCNH2KDM4ECYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | HTR1D 2946/4885KCNH2 1329/4885KDM4E 2853/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | HTR1D 2946/4885KCNH2 1329/4885KDM4E 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.